Latest Bambusa Therapeutics News & Updates
See the latest news and media coverage for Bambusa. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company
bambusatx.com- Headquarters
- BOSTON, United States
- Founded year
- 2024
- Company type
- Private company
- Number of employees
- 15–50
Last updated
Latest news about Bambusa Therapeutics (Bambusa)
In short: Bambusa advanced its bispecific antibody pipeline, completed Phase 1b/2a trial enrollment for BBT001, and secured significant Series A financing.
Company announcements
-
Bambusa completes enrollment in BBT001 trial
The Phase 1b/2a trial targets moderate-to-severe atopic dermatitis. Topline results are expected in mid-2026.
-
Bambusa announces Phase I data acceptance for BBT001
Data will be presented as an ePoster at AAD 2026 Annual Meeting. Company highlights rapid execution and best-in-class PK/PD profiles.
-
Bambusa announces BBT002 abstract acceptance for ATS 2026 oral presentation
BBT002 targets IL-4Rα and IL-5 for type 2 inflammation. Phase I data from healthy volunteers will be presented.
-
Bambusa receives BioSpace NextGen Class of 2026 recognition
It spotlights innovative biotech companies. The team and partners drive this momentum.
Media coverage
-
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of...
-
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
Immunogenicity: The incidence of ... safety or PK. "We were excited to highlight the data from our BBT001 clinical program for the first time at...
-
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in...
-
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to...
Track Bambusa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Bambusa competitors & trending companies
Browse news for competitors to Bambusa and other trending companies.
Chemomab
Lipum
Nektar
Agomab Therapeutics
Andon Labs
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One